vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and THOMSON REUTERS CORP (TRI). Click either name above to swap in a different company.

THOMSON REUTERS CORP is the larger business by last-quarter revenue ($1.8B vs $950.5M, roughly 1.9× Astrana Health, Inc.). THOMSON REUTERS CORP runs the higher net margin — 17.5% vs 0.7%, a 16.8% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 2.6%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

The second and current incarnation of News Corporation, doing business as News Corp, is an American mass media and publishing company headquartered at 1211 Avenue of the Americas in Midtown Manhattan, New York City. The company was formed on June 28, 2013, as a spin-off of the first News Corporation, whose legal successor was 21st Century Fox, which held its media and entertainment assets. Operating across digital real estate information, news media, book publishing, and cable television, New...

ASTH vs TRI — Head-to-Head

Bigger by revenue
TRI
TRI
1.9× larger
TRI
$1.8B
$950.5M
ASTH
Growing faster (revenue YoY)
ASTH
ASTH
+40.3% gap
ASTH
42.9%
2.6%
TRI
Higher net margin
TRI
TRI
16.8% more per $
TRI
17.5%
0.7%
ASTH

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
ASTH
ASTH
TRI
TRI
Revenue
$950.5M
$1.8B
Net Profit
$6.6M
$313.0M
Gross Margin
Operating Margin
1.9%
24.4%
Net Margin
0.7%
17.5%
Revenue YoY
42.9%
2.6%
Net Profit YoY
184.4%
-62.8%
EPS (diluted)
$0.12
$0.69

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
TRI
TRI
Q4 25
$950.5M
Q3 25
$956.0M
Q2 25
$654.8M
$1.8B
Q1 25
$620.4M
Q4 24
$665.2M
Q3 24
$478.7M
Q2 24
$486.3M
$1.7B
Q1 24
$404.4M
Net Profit
ASTH
ASTH
TRI
TRI
Q4 25
$6.6M
Q3 25
$373.0K
Q2 25
$9.4M
$313.0M
Q1 25
$6.7M
Q4 24
$-7.8M
Q3 24
$16.1M
Q2 24
$19.2M
$841.0M
Q1 24
$14.8M
Operating Margin
ASTH
ASTH
TRI
TRI
Q4 25
1.9%
Q3 25
2.0%
Q2 25
3.1%
24.4%
Q1 25
3.3%
Q4 24
0.1%
Q3 24
5.9%
Q2 24
6.2%
23.9%
Q1 24
7.5%
Net Margin
ASTH
ASTH
TRI
TRI
Q4 25
0.7%
Q3 25
0.0%
Q2 25
1.4%
17.5%
Q1 25
1.1%
Q4 24
-1.2%
Q3 24
3.4%
Q2 24
3.9%
48.3%
Q1 24
3.7%
EPS (diluted)
ASTH
ASTH
TRI
TRI
Q4 25
$0.12
Q3 25
$0.01
Q2 25
$0.19
$0.69
Q1 25
$0.14
Q4 24
$-0.14
Q3 24
$0.33
Q2 24
$0.40
$1.86
Q1 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
TRI
TRI
Cash + ST InvestmentsLiquidity on hand
$429.5M
$664.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$12.6B
Total Assets
$2.2B
$18.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
TRI
TRI
Q4 25
$429.5M
Q3 25
$463.4M
Q2 25
$342.1M
$664.0M
Q1 25
$260.9M
Q4 24
$290.8M
Q3 24
$350.3M
Q2 24
$327.7M
$1.7B
Q1 24
$337.3M
Stockholders' Equity
ASTH
ASTH
TRI
TRI
Q4 25
$779.3M
Q3 25
$775.5M
Q2 25
$765.5M
$12.6B
Q1 25
$745.4M
Q4 24
$712.7M
Q3 24
$704.6M
Q2 24
$678.9M
$11.6B
Q1 24
$653.5M
Total Assets
ASTH
ASTH
TRI
TRI
Q4 25
$2.2B
Q3 25
$2.2B
Q2 25
$1.4B
$18.0B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$1.3B
Q2 24
$1.3B
$18.4B
Q1 24
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
TRI
TRI
Operating Cash FlowLast quarter
$-2.9M
$746.0M
Free Cash FlowOCF − Capex
$-6.0M
FCF MarginFCF / Revenue
-0.6%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
-0.44×
2.38×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
TRI
TRI
Q4 25
$-2.9M
Q3 25
$10.0M
Q2 25
$90.9M
$746.0M
Q1 25
$16.6M
Q4 24
$-10.9M
Q3 24
$34.0M
Q2 24
$23.2M
$705.0M
Q1 24
$6.0M
Free Cash Flow
ASTH
ASTH
TRI
TRI
Q4 25
$-6.0M
Q3 25
$7.4M
Q2 25
$89.5M
Q1 25
$13.6M
Q4 24
$-13.5M
Q3 24
$31.7M
Q2 24
$20.4M
Q1 24
$5.6M
FCF Margin
ASTH
ASTH
TRI
TRI
Q4 25
-0.6%
Q3 25
0.8%
Q2 25
13.7%
Q1 25
2.2%
Q4 24
-2.0%
Q3 24
6.6%
Q2 24
4.2%
Q1 24
1.4%
Capex Intensity
ASTH
ASTH
TRI
TRI
Q4 25
0.3%
Q3 25
0.3%
Q2 25
0.2%
Q1 25
0.5%
Q4 24
0.4%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.1%
Cash Conversion
ASTH
ASTH
TRI
TRI
Q4 25
-0.44×
Q3 25
26.69×
Q2 25
9.65×
2.38×
Q1 25
2.48×
Q4 24
Q3 24
2.11×
Q2 24
1.21×
0.84×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

TRI
TRI

Segment breakdown not available.

Related Comparisons